CN112057424B - Troxerutin freeze-dried powder injection and preparation method thereof - Google Patents
Troxerutin freeze-dried powder injection and preparation method thereof Download PDFInfo
- Publication number
- CN112057424B CN112057424B CN202010985828.2A CN202010985828A CN112057424B CN 112057424 B CN112057424 B CN 112057424B CN 202010985828 A CN202010985828 A CN 202010985828A CN 112057424 B CN112057424 B CN 112057424B
- Authority
- CN
- China
- Prior art keywords
- troxerutin
- freeze
- dried powder
- powder injection
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 title claims abstract description 55
- 229960003232 troxerutin Drugs 0.000 title claims abstract description 55
- 238000002347 injection Methods 0.000 title claims abstract description 37
- 239000007924 injection Substances 0.000 title claims abstract description 37
- 239000000843 powder Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 22
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 15
- 239000001509 sodium citrate Substances 0.000 claims abstract description 15
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 14
- 238000004108 freeze drying Methods 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008215 water for injection Substances 0.000 claims abstract description 9
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- -1 hydroxyethyl rutin derivatives Chemical class 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
The invention discloses a troxerutin freeze-dried powder injection, which comprises the following raw materials in parts by weight: 400 parts of troxerutin, 6-10 parts of sodium citrate and 0.04-0.06 part of sodium sulfite. The invention also discloses a preparation method of the troxerutin freeze-dried powder injection, which comprises the following steps: dissolving troxerutin, sodium citrate and sodium sulfite with water for injection to obtain solution A; and filtering and sterilizing the solution A, subpackaging the solution A into containers, and then carrying out freeze-drying treatment to obtain the troxerutin freeze-dried powder injection. The invention has good stability, and related substances of the invention have no obvious change under the condition of long storage time.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to a troxerutin freeze-dried powder injection and a preparation method thereof.
Background
Troxerutin with molecular formula C 33 H 42 O 19 CAS number 7085-55-4. Troxerutin can inhibit platelet aggregation, prevent thrombosis, resist blood vessel injury caused by 5-hydroxytryptamine and bradykinin, and increase capillary bloodThe medicine has the effects of resisting the blood vessel, reducing the capillary permeability, preventing edema caused by the rise of the capillary permeability and having obvious protective effect on acute ischemic brain injury.
The troxerutin can be made into tablet, injection, lyophilized powder for injection, etc. At present, under the condition of long storage time, related substances of the troxerutin freeze-dried powder injection are easy to increase, the stability is low, and the product cost is indirectly increased.
Disclosure of Invention
Based on the technical problems in the background art, the invention provides a troxerutin freeze-dried powder injection and a preparation method thereof.
The invention provides a troxerutin freeze-dried powder injection which comprises the following raw materials in parts by weight: 400 parts of troxerutin, 6-10 parts of sodium citrate and 0.04-0.06 part of sodium sulfite.
Preferably, the raw materials comprise the following components in parts by weight: 400 parts of troxerutin, 8 parts of sodium citrate and 0.04 part of sodium sulfite.
The specification of the troxerutin freeze-dried powder injection can be 0.4g and the like.
The invention also provides a preparation method of the troxerutin freeze-dried powder injection, which comprises the following steps: dissolving troxerutin, sodium citrate and sodium sulfite with water for injection to obtain solution A; and filtering and sterilizing the solution A, subpackaging the solution A into containers, and then carrying out freeze-drying treatment to obtain the troxerutin freeze-dried powder injection.
Preferably, the procedure of the lyophilization process is: pre-freezing for 2h at-25 to-30 ℃, then heating to-5 to-15 ℃, freeze-drying for 7 to 9h, and then heating to 35 to 40 ℃ for drying for 5 to 7 h.
Preferably, the concentration of troxerutin in solution A is 0.2 g/ml.
Preferably, the solution A is subjected to a filter sterilization treatment by sequentially using 0.45 μm and 0.22 μm filter membranes.
In the preparation method, the solution A is filtered and sterilized, is subpackaged into containers, is covered with a rubber plug, is subjected to freeze-drying treatment, finally rejects such as plug missing, gland shifting, bottle breakage and the like are removed, and qualified products are rolled with an aluminum cover to obtain the troxerutin freeze-dried powder injection.
Has the beneficial effects that:
the invention selects sodium citrate and sodium sulfite as auxiliary materials, matches with troxerutin in proper proportion, and combines with proper preparation technology, so that the prepared troxerutin freeze-dried powder injection has good stability, and the pH, related substances and content of the troxerutin freeze-dried powder injection have no obvious change under the condition of long storage time.
Detailed Description
The technical solution of the present invention will be described in detail below with reference to specific examples.
Example 1
A troxerutin freeze-dried powder injection comprises the following raw materials in parts by weight: 400 parts of troxerutin, 6 parts of sodium citrate and 0.06 part of sodium sulfite.
The preparation method of the troxerutin freeze-dried powder injection comprises the following steps: adding troxerutin, sodium citrate and sodium sulfite into 1000ml of water for injection according to the prescription amount for dissolving, and slowly adding the water for injection to 2000ml to obtain a solution A with the concentration of the troxerutin being 0.2 g/ml; pre-filtering the solution A by a microporous filter with the aperture of 0.45 mu m, sterilizing and filtering by a microporous filter with the aperture of 0.22 mu m, subpackaging the filtrate into injection bottles (2 ml filtrate per bottle), capping a rubber plug (half plugging state), transferring into a freeze-drying box, pre-freezing at-30 ℃ for 2h, heating to-10 ℃ for freeze-drying for 8h, heating at a constant speed to 37 ℃ for drying for 6h, removing unqualified products such as missing plugs, gland shifting, bottle breakage and the like, and rolling an aluminum cover on the qualified products to obtain the troxerutin freeze-dried powder injection.
Example 2
A troxerutin freeze-dried powder injection comprises the following raw materials in parts by weight: 400 parts of troxerutin, 10 parts of sodium citrate and 0.04 part of sodium sulfite.
The preparation method of the troxerutin freeze-dried powder injection comprises the following steps: adding troxerutin, sodium citrate and sodium sulfite into 1000ml of water for injection according to the prescription amount for dissolving, and then slowly adding the water for injection to 2000ml to obtain a solution A with the concentration of the troxerutin being 0.2 g/ml; pre-filtering the solution A by a microporous filter with the aperture of 0.45 mu m, sterilizing and filtering by a microporous filter with the aperture of 0.22 mu m, subpackaging the filtrate into injection bottles (2 ml filtrate per bottle), capping a rubber plug (half plugging state), transferring into a freeze-drying box, pre-freezing at-25 ℃ for 2h, then heating to-5 ℃ for freeze-drying for 9h, then heating to 35 ℃ at a constant speed for drying for 7h, removing unqualified products such as missing plugs, gland shifting, bottle breakage and the like, and rolling an aluminum cover on the qualified products to obtain the troxerutin freeze-dried powder injection.
Example 3
A troxerutin freeze-dried powder injection comprises the following raw materials in parts by weight: 400 parts of troxerutin, 8 parts of sodium citrate and 0.04 part of sodium sulfite.
The preparation method of the troxerutin freeze-dried powder injection comprises the following steps: adding troxerutin, sodium citrate and sodium sulfite into 1000ml of water for injection according to the prescription amount for dissolving, and slowly adding the water for injection to 2000ml to obtain a solution A with the concentration of the troxerutin being 0.2 g/ml; pre-filtering the solution A by a microporous filter with the aperture of 0.45 mu m, sterilizing and filtering by a microporous filter with the aperture of 0.22 mu m, subpackaging the filtrate into injection bottles (2 ml filtrate per bottle), capping a rubber plug (half plugging state), transferring into a freeze-drying box, pre-freezing at-30 ℃ for 2h, heating to-15 ℃, freeze-drying for 7h, heating at a constant speed to 37 ℃, drying for 6h, removing unqualified products such as missing plugs, gland shifting, bottle breakage and the like, and rolling an aluminum cover on the qualified products to obtain the troxerutin freeze-dried powder injection.
The long-term stability test was carried out on troxerutin lyophilized powder for injection (formula: troxerutin and sodium citrate, manufactured by Kaikang pharmaceutical Co., Ltd.) sold in example 3 and commercially available troxerutin lyophilized powder for injection, and the results are shown in Table 1.
TABLE 1 Long term stability test results
Remarking: other hydroxyethyl rutin derivatives are hydroxyethyl rutin, dihydroxyethyl rutin, and tetrahydroxyethyl rutin.
As can be seen from table 1: compared with the commercially available troxerutin freeze-dried powder injection, the pH value, related substances and content of the troxerutin freeze-dried powder injection have no obvious change under the condition of long storage time, and the stability is good.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (3)
1. A preparation method of troxerutin freeze-dried powder injection is characterized by comprising the following raw materials in parts by weight: 400 parts of troxerutin, 8 parts of sodium citrate and 0.04 part of sodium sulfite; the method comprises the following steps: dissolving troxerutin, sodium citrate and sodium sulfite with water for injection to obtain solution A; filtering and sterilizing the solution A, subpackaging the solution A into containers, and then carrying out freeze-drying treatment to obtain troxerutin freeze-dried powder injection; the concentration of troxerutin in the solution A is 0.2 g/ml.
2. The preparation method of the troxerutin freeze-dried powder injection according to claim 1, wherein the freeze-drying process comprises the following steps: pre-freezing for 2h at-25 to-30 ℃, then heating to-5 to-15 ℃, freeze-drying for 7 to 9h, and then heating to 35 to 40 ℃ for drying for 5 to 7 h.
3. The preparation method of the troxerutin freeze-dried powder injection according to claim 1, wherein the solution A is subjected to filtration sterilization treatment by using filter membranes with the pore diameter of 0.45 μm and 0.22 μm in sequence.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010985828.2A CN112057424B (en) | 2020-09-18 | 2020-09-18 | Troxerutin freeze-dried powder injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010985828.2A CN112057424B (en) | 2020-09-18 | 2020-09-18 | Troxerutin freeze-dried powder injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112057424A CN112057424A (en) | 2020-12-11 |
| CN112057424B true CN112057424B (en) | 2022-09-16 |
Family
ID=73680748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010985828.2A Active CN112057424B (en) | 2020-09-18 | 2020-09-18 | Troxerutin freeze-dried powder injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112057424B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114569550A (en) * | 2022-03-08 | 2022-06-03 | 石家庄四药有限公司 | Troxerutin injection and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035933A1 (en) * | 1998-12-11 | 2000-06-22 | Laboratoires Negma | Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
| CN1729989A (en) * | 2004-09-06 | 2006-02-08 | 成都百康医药工业药理毒理研究院 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
| WO2011034464A1 (en) * | 2009-09-15 | 2011-03-24 | Общество С Ограниченной Ответственностью "Герофарм" | Injectable dosage form for the treatment of an acute ischaemic insult and cranial trauma, manufacturing method and use |
| CN102580055A (en) * | 2012-03-09 | 2012-07-18 | 张睿 | Troxerutin-cerebroprotein hydrolysate dripping pill and preparation method thereof |
| CN105079015A (en) * | 2014-05-21 | 2015-11-25 | 蚌埠丰原涂山制药有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
| CN110339172A (en) * | 2019-07-02 | 2019-10-18 | 湖北美林药业有限公司 | Troxerutin for Injection and preparation method thereof |
-
2020
- 2020-09-18 CN CN202010985828.2A patent/CN112057424B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035933A1 (en) * | 1998-12-11 | 2000-06-22 | Laboratoires Negma | Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
| CN1729989A (en) * | 2004-09-06 | 2006-02-08 | 成都百康医药工业药理毒理研究院 | Medicine composition for treating cardiovascular and cerebrovascular disease and its preparation method |
| WO2011034464A1 (en) * | 2009-09-15 | 2011-03-24 | Общество С Ограниченной Ответственностью "Герофарм" | Injectable dosage form for the treatment of an acute ischaemic insult and cranial trauma, manufacturing method and use |
| CN102580055A (en) * | 2012-03-09 | 2012-07-18 | 张睿 | Troxerutin-cerebroprotein hydrolysate dripping pill and preparation method thereof |
| CN105079015A (en) * | 2014-05-21 | 2015-11-25 | 蚌埠丰原涂山制药有限公司 | Troxerutin freeze-dried powder injection and preparation method thereof |
| CN110339172A (en) * | 2019-07-02 | 2019-10-18 | 湖北美林药业有限公司 | Troxerutin for Injection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 曲克芦丁注射液的稳定性研究;李勃，等;《北方药学》;20061231;第15-16页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112057424A (en) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100506213C (en) | Lansoprazole freeze-dried powder for injection and preparing method thereof | |
| CN112057424B (en) | Troxerutin freeze-dried powder injection and preparation method thereof | |
| IE890854L (en) | Lyophilized pharmaceutical preparations | |
| CN112007000A (en) | Espressole sodium freeze-dried powder injection and preparation method thereof | |
| AU598602B2 (en) | Ifosphamide lyophilisate and process for its preparation | |
| CN103768028A (en) | Esomeprazole sodium sterile lyophilized powder for injection and preparation process of lyophilized powder | |
| CN103585018A (en) | New freeze-drying method for reduced glutathione for injection | |
| CN113081975B (en) | Preparation method of clindamycin phosphate freeze-dried powder injection for injection | |
| CN101829065B (en) | Lansoprazole composition freeze-dried powder for injection | |
| CN114159396A (en) | Espressol omeprazole sodium freeze-dried preparation for injection and preparation method thereof | |
| CN107714664A (en) | Aspirin-Al-lysine for injection freeze drying powder injection and preparation method thereof | |
| JPH0374643B2 (en) | ||
| CN114681409A (en) | Famotidine for injection and preparation method thereof | |
| CN103830166B (en) | Preparation method of hypertonic resuscitation fluid and application thereof | |
| CN113476412A (en) | Preparation method of piracetam freeze-dried powder injection for injection | |
| CN110680807A (en) | Preparation method of propyl gallate for injection | |
| CN112353799A (en) | Cimetidine composition for injection and preparation method and application thereof | |
| CN113143868B (en) | Papaverine hydrochloride for injection and preparation method thereof | |
| CN113230216B (en) | Piracetam freeze-dried powder injection for injection and preparation method thereof | |
| CN114685581B (en) | Troxerutin for injection and preparation process thereof | |
| CN108653216B (en) | Tigecycline for injection | |
| CN113069420B (en) | Sodium ozagrel for injection and preparation method thereof | |
| CN109172626B (en) | Wild chrysanthemum injection and preparation method thereof | |
| JPS63277628A (en) | Antitumor agent | |
| CN113332291A (en) | Preparation method of pentoxifylline powder injection for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee after: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee after: Hefei Kangnuo Biopharmaceutical Co.,Ltd. Address before: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee before: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee before: Hefei Kangnuo biopharmaceutical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee after: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee after: Kangnuo Biopharmaceutical Co.,Ltd. Address before: 475000 66 south section of Jinming Road, Kaifeng, Henan Patentee before: KAIFENG KANGNUO PHARMACEUTICAL Co.,Ltd. Patentee before: Hefei Kangnuo Biopharmaceutical Co.,Ltd. |